vs

Side-by-side financial comparison of Angel Oak Mortgage REIT, Inc. (AOMR) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $10.9M, roughly 1.8× Angel Oak Mortgage REIT, Inc.). Angel Oak Mortgage REIT, Inc. runs the higher net margin — 103.9% vs -177.4%, a 281.3% gap on every dollar of revenue. On growth, Angel Oak Mortgage REIT, Inc. posted the faster year-over-year revenue change (10.4% vs -11.5%). Over the past eight quarters, Angel Oak Mortgage REIT, Inc.'s revenue compounded faster (12.7% CAGR vs -12.2%).

Angel Oak Mortgage REIT, Inc. is a U.S.-based real estate investment trust focused on investing in residential mortgage assets, including non-agency mortgage-backed securities, residential mortgage loans, and credit-linked real estate instruments. It serves U.S. institutional and retail investors, targeting competitive risk-adjusted returns through regular income and long-term capital growth.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

AOMR vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.8× larger
LAB
$19.6M
$10.9M
AOMR
Growing faster (revenue YoY)
AOMR
AOMR
+21.9% gap
AOMR
10.4%
-11.5%
LAB
Higher net margin
AOMR
AOMR
281.3% more per $
AOMR
103.9%
-177.4%
LAB
Faster 2-yr revenue CAGR
AOMR
AOMR
Annualised
AOMR
12.7%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
AOMR
AOMR
LAB
LAB
Revenue
$10.9M
$19.6M
Net Profit
$11.3M
$-34.7M
Gross Margin
48.5%
Operating Margin
-168.5%
Net Margin
103.9%
-177.4%
Revenue YoY
10.4%
-11.5%
Net Profit YoY
175.2%
-28.8%
EPS (diluted)
$0.44
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AOMR
AOMR
LAB
LAB
Q4 25
$10.9M
Q3 25
$10.2M
$19.6M
Q2 25
$9.9M
$21.8M
Q1 25
$10.1M
$40.8M
Q4 24
$9.9M
Q3 24
$9.0M
$22.1M
Q2 24
$9.5M
$22.5M
Q1 24
$8.6M
$45.5M
Net Profit
AOMR
AOMR
LAB
LAB
Q4 25
$11.3M
Q3 25
$11.4M
$-34.7M
Q2 25
$767.0K
$-33.5M
Q1 25
$20.5M
$-26.0M
Q4 24
$-15.1M
Q3 24
$31.2M
$-26.9M
Q2 24
$-273.0K
$-45.7M
Q1 24
$12.9M
$-32.2M
Gross Margin
AOMR
AOMR
LAB
LAB
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
AOMR
AOMR
LAB
LAB
Q4 25
Q3 25
-168.5%
Q2 25
7.7%
-118.1%
Q1 25
-80.8%
Q4 24
-152.6%
Q3 24
-120.9%
Q2 24
-1.4%
-134.5%
Q1 24
-132.2%
Net Margin
AOMR
AOMR
LAB
LAB
Q4 25
103.9%
Q3 25
112.1%
-177.4%
Q2 25
7.7%
-153.7%
Q1 25
203.5%
-63.8%
Q4 24
-152.6%
Q3 24
345.9%
-122.0%
Q2 24
-2.9%
-203.3%
Q1 24
150.1%
-70.6%
EPS (diluted)
AOMR
AOMR
LAB
LAB
Q4 25
$0.44
Q3 25
$0.46
$-0.09
Q2 25
$0.03
$-0.09
Q1 25
$0.87
$-0.07
Q4 24
$-0.62
Q3 24
$1.29
$-0.07
Q2 24
$-0.01
$-0.12
Q1 24
$0.51
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AOMR
AOMR
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$41.6M
$129.4M
Total DebtLower is stronger
$2.3B
Stockholders' EquityBook value
$267.5M
$399.7M
Total Assets
$2.7B
$539.6M
Debt / EquityLower = less leverage
8.51×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AOMR
AOMR
LAB
LAB
Q4 25
$41.6M
Q3 25
$51.6M
$129.4M
Q2 25
$40.5M
$158.6M
Q1 25
$38.7M
$150.9M
Q4 24
$40.8M
Q3 24
$42.1M
$210.6M
Q2 24
$44.0M
$269.8M
Q1 24
$39.4M
$287.1M
Total Debt
AOMR
AOMR
LAB
LAB
Q4 25
$2.3B
Q3 25
$2.2B
Q2 25
Q1 25
Q4 24
$1.8B
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
AOMR
AOMR
LAB
LAB
Q4 25
$267.5M
Q3 25
$264.2M
$399.7M
Q2 25
$246.4M
$424.5M
Q1 25
$251.5M
$454.6M
Q4 24
$239.0M
Q3 24
$265.1M
$489.3M
Q2 24
$255.8M
$510.3M
Q1 24
$263.3M
$577.3M
Total Assets
AOMR
AOMR
LAB
LAB
Q4 25
$2.7B
Q3 25
$2.6B
$539.6M
Q2 25
$2.6B
$557.0M
Q1 25
$2.7B
$579.6M
Q4 24
$2.3B
Q3 24
$2.3B
$681.5M
Q2 24
$2.1B
$708.7M
Q1 24
$2.3B
$777.7M
Debt / Equity
AOMR
AOMR
LAB
LAB
Q4 25
8.51×
Q3 25
8.37×
Q2 25
Q1 25
Q4 24
7.62×
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AOMR
AOMR
LAB
LAB
Operating Cash FlowLast quarter
$-407.0M
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
4.5%
Cash ConversionOCF / Net Profit
-35.96×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AOMR
AOMR
LAB
LAB
Q4 25
$-407.0M
Q3 25
$-173.4M
$-22.2M
Q2 25
$20.6M
$-20.7M
Q1 25
$-201.7M
$-30.3M
Q4 24
$-221.5M
Q3 24
$-212.4M
$-27.9M
Q2 24
$-24.2M
$-39.0M
Q1 24
$40.2M
$-62.5M
Free Cash Flow
AOMR
AOMR
LAB
LAB
Q4 25
Q3 25
$-23.1M
Q2 25
$-22.6M
Q1 25
$-35.3M
Q4 24
Q3 24
$-30.1M
Q2 24
$-41.0M
Q1 24
$-63.3M
FCF Margin
AOMR
AOMR
LAB
LAB
Q4 25
Q3 25
-118.1%
Q2 25
-103.6%
Q1 25
-86.6%
Q4 24
Q3 24
-136.4%
Q2 24
-182.2%
Q1 24
-138.9%
Capex Intensity
AOMR
AOMR
LAB
LAB
Q4 25
Q3 25
4.5%
Q2 25
8.7%
Q1 25
12.4%
Q4 24
Q3 24
10.2%
Q2 24
8.6%
Q1 24
1.7%
Cash Conversion
AOMR
AOMR
LAB
LAB
Q4 25
-35.96×
Q3 25
-15.19×
Q2 25
26.92×
Q1 25
-9.83×
Q4 24
Q3 24
-6.81×
Q2 24
Q1 24
3.12×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AOMR
AOMR

Nonrelated Party$6.4M59%
Other$4.5M41%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons